IL166103A0 - Pyrrolidine derivatives and their use - Google Patents

Pyrrolidine derivatives and their use

Info

Publication number
IL166103A0
IL166103A0 IL16610305A IL16610305A IL166103A0 IL 166103 A0 IL166103 A0 IL 166103A0 IL 16610305 A IL16610305 A IL 16610305A IL 16610305 A IL16610305 A IL 16610305A IL 166103 A0 IL166103 A0 IL 166103A0
Authority
IL
Israel
Prior art keywords
sub
sup
pyrrolidine derivatives
forms
dysmenorrhea
Prior art date
Application number
IL16610305A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL166103A0 publication Critical patent/IL166103A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16610305A 2002-07-05 2005-01-03 Pyrrolidine derivatives and their use IL166103A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100784 2002-07-05
PCT/EP2003/050286 WO2004005249A1 (en) 2002-07-05 2003-07-04 Pyrrolidine derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
IL166103A0 true IL166103A0 (en) 2006-01-15

Family

ID=30011225

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16610305A IL166103A0 (en) 2002-07-05 2005-01-03 Pyrrolidine derivatives and their use

Country Status (19)

Country Link
US (1) US7115754B2 (pl)
EP (1) EP1532109B1 (pl)
JP (1) JP4851085B2 (pl)
CN (1) CN1330633C (pl)
AT (1) ATE442354T1 (pl)
BR (1) BR0312586A (pl)
CA (1) CA2487532C (pl)
DE (1) DE60329189D1 (pl)
EA (1) EA008479B1 (pl)
ES (1) ES2330841T3 (pl)
HR (1) HRP20041208A2 (pl)
IL (1) IL166103A0 (pl)
MX (1) MXPA05000326A (pl)
NO (1) NO20050612L (pl)
PL (1) PL374666A1 (pl)
RS (1) RS115804A (pl)
UA (1) UA78058C2 (pl)
WO (1) WO2004005249A1 (pl)
ZA (1) ZA200409820B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444225B1 (en) * 2001-06-18 2012-10-10 Merck Serono SA Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists.
RU2380110C1 (ru) * 2008-06-16 2010-01-27 Институт прикладной механики Уральского отделения Российской Академии Наук Способ стимуляции родов по н.а. михайловой
US10722645B2 (en) 2011-12-21 2020-07-28 Deka Products Limited Partnership Syringe pump, and related method and system
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EP3753921A1 (en) 2014-07-02 2020-12-23 ObsEva S.A. Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
PL3037101T3 (pl) * 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
ES2915948T3 (es) 2016-01-04 2022-06-27 ObsEva SA Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
TW202435864A (zh) 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
ES2261404T3 (es) 2000-03-27 2006-11-16 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina utiles como inhibidores de bax.

Also Published As

Publication number Publication date
EA200500133A1 (ru) 2005-08-25
ZA200409820B (en) 2006-07-26
RS115804A (sr) 2007-02-05
MXPA05000326A (es) 2005-03-31
CA2487532C (en) 2011-03-08
CN1330633C (zh) 2007-08-08
HRP20041208A2 (en) 2005-06-30
JP2005533828A (ja) 2005-11-10
EP1532109A1 (en) 2005-05-25
NO20050612L (no) 2005-02-03
EA008479B1 (ru) 2007-06-29
WO2004005249A1 (en) 2004-01-15
AU2003254498A1 (en) 2004-01-23
EP1532109B1 (en) 2009-09-09
JP4851085B2 (ja) 2012-01-11
US7115754B2 (en) 2006-10-03
ATE442354T1 (de) 2009-09-15
ES2330841T3 (es) 2009-12-16
PL374666A1 (pl) 2005-10-31
DE60329189D1 (de) 2009-10-22
UA78058C2 (en) 2007-02-15
CA2487532A1 (en) 2004-01-15
HK1076107A1 (en) 2006-01-06
BR0312586A (pt) 2005-04-12
CN1678576A (zh) 2005-10-05
US20060004020A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
BR0314688A (pt) Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
DK0841929T3 (da) Quinoloner og deres terapeutiske anvendelse
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
SE0400043D0 (sv) New compounds
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
HRP20041208A2 (en) Pyrrolidine derivatives as oxytocin antagonists
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
ES2202156T3 (es) Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
SI1532131T1 (sl) Motilidne spojine
DE50304891D1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
NO20060718L (no) Substituerte tiofoner og deres anvendelse
SE0104333D0 (sv) Therapeutic agents